VIB

1) Challenge - Capital Market Reform: European biotech IPOs underperform due to a fragmented and underdeveloped public market infrastructure. Low liquidity, lack of specialist analyst coverage, and poor regulatory fit discourage long-term investment and scale.

1) Challenge - Addressing the funding gap European biotech companies face a severe shortage of growth-stage financing, particularly in Phase II and III clinical development. The investment ecosystem is heavily weighted toward early-stage assets, lacking the scale and continuity to support companies as they mature.

VIB welcomes the European Commission's initiative to develop a European Biotech Act II as a key pillar of Europe's competitiveness agenda. Europe possesses world-leading capabilities in biotechnology research and innovation. However, despite its scientific excellence, Europe continues to underperform in translating discoveries into scalable companies, industrial deployment and market impact.

VIB Verenigde Isolatie Branche Nederland (United Insulation Industry Netherlands ) On a daily base VIB members recognize minimum design and poor condition of insulation, resulting in a waste of Energy. We are convinced that substantial energy savings can be achieved by: standardization and upgrading insulation specification , for example Energy classes.